NSE filing, NSE: ZIMLAB. Summary written from the filing by ALFA Finder's alert engine.
Zim Laboratories Ltd: key numbers
- Share price
- ₹143.10
- Market cap
- ₹767.9 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 207.8×Sector 46.5×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Other Announcement
Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.
Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Zim Laboratories Acquisition Worth ₹1.56 Cr
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
- Value
- ₹1.56 Cr
Other credit rating announcements
All →GSPL Transmission Credit Rating
CARE Ratings assigned GSPL Transmission a CARE AA+ rating on bank facilities with a stable outlook. The rating cites nil debt and strong liquidity.
Meghmani Organics Credit Rating
India Ratings assigned Meghmani Organics' bank loan facilities of INR 11,000 million a rating of IND A/Stable/IND A1. The filing encloses the rating letter and a facilities breakup.
JSW Cement Credit Rating
CRISIL reaffirmed JSW Cement's long-term rating at AA-/Stable and its short-term ratings at A1+. No new borrowing or fund raise is announced.
Tejas Networks Credit Rating
ICRA reaffirmed Tejas Networks' [ICRA]A+(Stable) long-term rating and [ICRA]A1+ short-term rating. The rating covers Rs.6,000 Crore of credit facilities and a Rs.500 Crore CP programme.
HDB Financial Services Credit Rating
CARE Ratings reaffirmed HDB Financial Services' AAA rating with Stable outlook across its debt instruments. Its A1+ short-term rating was also reaffirmed.
Asian Energy Services Credit Rating
Asian Energy Services Limited disclosed that CRISIL maintained its 'Watch Developing' rating on INR 317.5 Crore of bank facilities. The watch continues pending final Ministry of Petroleum approval for the merger of its parent, Oilmax Energy.